First Quadrant’s Acadia Pharmaceuticals ACAD Stock Holding History

First Quadrant’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-16,500	Closed	-$385K	–	139
2021 Q4	$385K	Buy	16,500 +4,500	+38%	+$90.5K	0.04%	274
2021 Q3	$199K	Buy	+12,000	New	+$231K	0.02%	341
2019 Q2	–	Sell	-2,198	Closed	-$59K	–	696
2019 Q1	$59K	Buy	+2,198	New	+$51.3K	﹤0.01%	630

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

First Quadrant's ACAD Position: Q1 2022 in Review

First Quadrant sold out of Acadia Pharmaceuticals (ACAD) in Q1 2022, closing a stake of 16,500 shares — an estimated $385K sold.

First Quadrant first reported a position in ACAD in Q1 2019 and held it in 3 quarters. The position peaked at $385K in Q4 2021. 262 funds tracked by Wall St. Rank hold ACAD as of Q1 2022.

First Quadrant reported no remaining Acadia Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
First Quadrant sold 16,500 Acadia Pharmaceuticals shares in Q1 2022, an estimated $385K.
First Quadrant first reported a position in Acadia Pharmaceuticals in Q1 2019 and held it in 3 quarters.
First Quadrant's Acadia Pharmaceuticals position peaked at $385K in Q4 2021.
262 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2022.

Based on First Quadrant's 13F filing for Q1 2022, filed 21 Apr 2022.